Major Depressive Disorder Clinical Trial
— R2D2Official title:
Psychophysiological Study of Pain Perception in Depressed Patients With Suicidal Risk
Joiner's interpersonal theory of suicide postulates that the wish of death comes from feelings of perceived burdensomeness and thwarted belongingness. But, only people who have acquired the capability to kill themselves will attempt suicide. The acquired capability refers to a reduction of fear to death, and a higher pain tolerance. Indeed, to commit suicide involves to endure pain during the act. Thus, higher pain tolerance seems to be a necessary feature for suicidal act. Past studies have shown higher pain threshold and tolerance in suicidal patients, whatever the stimulus was (electric, thermic or mechanical), compared to patients without suicide history. Moreover, Caceda and colleagues demonstrated higher pain threshold in recent suicide attempters (suicidal act within 72h) compared with depressed patients. Five days after the initial evaluation, pain threshold of recent suicide attempters decreased to be similar to depressed patients with suicidal ideation. Therefore, it may exist a specific state during which the pain tolerance is increased. During this "hypoalgesic state" patients with suicidal ideation could attempt suicide to get relief from suffering. However, little is known about the specific mechanisms that are responsible for the higher pain threshold and tolerance in suicide attempters. Pain is a dynamic system that results from excitatory and inhibitory messages. The modification of one of these mechanisms could explain the higher tolerance in recent suicide attempters. Three of them are of particular interest: 1. The conditioned pain modulation (CPM) is a modulatory pain mechanism. CPM works through descending pathway that reaches the spinal cord and modulates pain processing from the first nociceptive synapse.In recent suicidal patients, an increase of the CPM could explain higher pain tolerance. 2. The "wind-up" mechanism is defined as the highest excitability of the second order nerve. Even if the stimulus remains stable, pain continuously raises. In recent suicide attempters, a reduction of this mechanism could explain higher pain tolerance. 3. The threshold of Aδ and C nociceptors. If a nociceptive fiber is less excitable than the other, it would explain higher pain threshold.
Status | Recruiting |
Enrollment | 153 |
Est. completion date | March 2025 |
Est. primary completion date | November 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria for all patients: - Woman; - Being aged between 18 and 65 years; - Currently meeting the DSM-5 major depressive episode criteria; - Being able to understand the nature, purpose and methodology of the study and agreeing to cooperate during the assessments; - Having signed informed consent; - Being affiliated with a social security or equivalent. Inclusion Criteria specific to each group: - Recent attempters: women having recently attempted suicide (less than 72 hours) - Past attempters: women having a past suicide attempt (more than 72 hours) - Affective control: women without lifetime history of suicidal behaviour (affective control group). Exclusion Criteria for all patients: - Existence of current psychotic or mixed characteristics; - Lifetime history of schizoaffective disorder or schizophrenia; - Current substance dependence (within the last 6 months); - Existence of mental retardation or serious medical comorbidity interfering with measures (HIV, diabetes, cancer, chronic inflammatory pathology, neurological disorder); - Having taken painkillers within the last 24 hours preceding the evaluation; - Existence of a usual or current treatment with analgesics or NSAIDs (daily analgesic treatment more than 3 months); - Existence of a sensory or cognitive handicap; - Pregnant or lactating woman. |
Country | Name | City | State |
---|---|---|---|
France | University Hospital of Montpellier | Montpellier | Occitanie |
France | Clinic La Lironde | Saint Gély du Fesc | Occitanie |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier | Clinea psychiatrie France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effectiveness of the conditioned pain modulation | The criterion will be the average difference of perceived pain (CoVAS measure) before and after modulation, i.e. before and after the cold pressor task.
It's postulated that recent suicidal patients will have a higher efficacity of CPM than past suicidal patients and depressed affective controls. |
During painful stimulations which are assessed 24 hours after the inclusion | |
Secondary | Effectiveness of the Wind-up mechanism | The criterion will be the slope of the progressive rise of the painful sensation (CoVAS measure).
It's postulated that recent suicidal patients will have a weaker wind-up mechanism than in the two other groups. |
During painful stimulations which are assessed 24 hours after the inclusion | |
Secondary | Ad and C fibers thresholds | The criterion will be the first temperature for which the participant perceived pain for each fiber.
It's postulated that recent suicidal patients will have a higher threshold for Ad or C fiber than in the two other groups. |
During painful stimulations which are assessed 24 hours after the inclusion | |
Secondary | Pleasantness associated with social touch | The criterion will be the score on the Likert scale. It's postulated that recent suicidal patients will have a lower score than the 2 other groups. | During painful stimulations which are assessed 24 hours after the inclusion | |
Secondary | Emotional Reactivity Score | The score ranges from 0 to 84. A higher score indicates an elevated emotional reactivity. It's postulated that this score will be correlated with the primary outcome. | At inclusion | |
Secondary | Emotional Regulation Score | The score ranges from 36 to 180. A higher score indicates more difficulties to regulate her emotions. It's postulated that this score will be correlated with the primary outcome. | At inclusion | |
Secondary | Dissociative experiences score | The score ranges from 0 to 100. A higher score indicates a higher frequency of dissociative experiences. It's postulated that this score will be correlated with the primary outcome. | At inclusion | |
Secondary | Body investment score | The score ranges from 24 to 120. A higher score indicates more investment toward the body. It's postulated that this score will be correlated with the primary outcome. | At inclusion | |
Secondary | Acquired Capability of Suicide Scale | The score ranges from 0 to 80. This scale mainly assess the fearlessness about death, about dying and a general component of fearlessness. A higher score indicates fearlessness. It's postulated that this score will be correlated with the primary outcome. | At inclusion | |
Secondary | Functional connectivity in saliency's network (ID-RCB :2023-A00213-42) | The functional connectivity will be represent by ALFF (Amplitude of Low Frenquency Fluctuations) and ReHo (RegionalHomogeneity) measures | During an IRM which is assessed 8 days after visite 1 or after inclusion until 24 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |